Expression Of Somatostatin Receptor, Estrogen And Progesterone Receptor In Human Endometrial Cancer

Objective:To study the expression of somatostatin receptor(SSTR) in human endometrial carcinomas and its significance.To determine the relationship between the expression of SSTR and estrogen, progesterone receptor (ER, PR) expression.Method:Immunohistochemical staining of SSTR,ER and PR was performed by the standard streptavidin-peroxidase(SP) technique for the paraffin sections of 60 endometrial cancers. The relationships between SSTR expression and clinicopathological features ,ER,PR expression were analyzed.Results:1.The expression of SSTRSomatostatin receptor-like Immunoreactivity was located at the plasma membrane.The positive rate of SSTR in 60 endometrial cancers was SSTR170%, SSTR215%, SSTR321.7%, SSTR423.3%, SSTR518.3%.The expression of somatostatin receptor subtypes was independent of age, tumor stage,histological grade and tumor depth except that the expression of SSTR3 , SSTR4 in middle to well differentiated group was significantly higher than that in poorly differentiated group(P<0.05). 2.The expression of ER, PRER and PR positive rates were 46.7% and 70% in 60 endometrial cancers.The positive rates of ER/PR in middle to well differentiated and deep myometrial invasionendometrial cancers were significantly higher than those in poorly differentiated andshallow myometrial invasion groups (P<0.05) . But no significant relationship wasfound between the positive rates of ER/PR and clinicopathologic stage(P>0.05).3.Correlation between SSTR expression and ER/PR expression in endometrialcarcinomaSSTR2, SSTR4 expression was correlated significantly with ER expression(P< 0.05),while SSTR3, SSTR5 expression was correlated significantly with PR expression (P <0.05).Conclutions:There is positive expression of SSTR in human endometrial cancers. The expression of some SSTR subtypes was correlated with ER, PR expression. We suggest that a subgroup of receptor-positive endometrial cancers may be a potential target for diagnose,treatment and prediction of prognosis with somatostatin receptor subtype-selective analogs.